<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533960</url>
  </required_header>
  <id_info>
    <org_study_id>RASUNOA-Prime</org_study_id>
    <nct_id>NCT02533960</nct_id>
  </id_info>
  <brief_title>Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime</brief_title>
  <acronym>RASUNOA-Prime</acronym>
  <official_title>Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an
      investigator-initiated study, is a German multicenter, prospective, observational registry.
      It is performed at about 50 certified stroke-units and supported by an unrestricted grant
      from different pharmaceutical companies to the Heidelberg University Hospital. RASUNOA-Prime
      is designed to assess the emergency management of acute ischemic and hemorrhagic stroke
      patients with atrial fibrillation (AF) under different anticoagulation schemes pre stroke:
      Non-vitamin K antagonist oral anticoagulants (NOAC), Vitamin K antagonists (VKA), and no
      anticoagulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this observational cohort study is to assess routine emergency management
      of acute stroke patients with AF under different anticoagulation schemes before the index
      stroke.

      The investigators will address the following aims and objectives:

        1. Describing emergency management of stroke patients (IS and ICH) with AF in clinical
           routine including early diagnostic, therapeutic and preventive procedures and assessing
           variations in emergency management of patients with AF by anticoagulation schemes pre
           stroke.

        2. Identifying variations in risk of early complications (e.g. symptomatic secondary
           intracerebral haemorrhage in ischemic stroke patients) with AF by different
           anticoagulation schemes pre stroke.

        3. Determining factors influencing outcome of stroke patients with AF at three months and
           clarifying the potential influence of different anticoagulation schemes pre stroke.

      The registry consists of 2 separate substudies that cover two different patient cohorts:
      ischemic stroke and intracerebral hemorrhage.

      The study will collect information from prospectively enrolling Neurology departments with
      certified stroke units across Germany.

      The principal investigator, Prof. Dr. med. Roland Veltkamp, is affiliated with Imperial
      College London, UK, and Heidelberg University Hospital, Germany.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary hypothesis (ischemic stroke substudy)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of less than 2 weeks&quot;</time_frame>
    <description>Intracerebral hemorrhage complications (i.e. sICH, according to NINDS and SITS-MOST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary hypothesis (hemorrhagic stroke substudy)</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of relevant secondary hematoma expansion on follow-up neuroimaging (hematoma expansion of &gt;= 33% or 6 mL)</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Oral Anticoagulation</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>NOAC</arm_group_label>
    <description>Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).
Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VKA</arm_group_label>
    <description>Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).
Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without OAC</arm_group_label>
    <description>Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.
Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>not applicable (observational study)</intervention_name>
    <description>Observational study without study related intervention.</description>
    <arm_group_label>NOAC</arm_group_label>
    <arm_group_label>VKA</arm_group_label>
    <arm_group_label>Without OAC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute stroke patients with atrial fibrillation (AF) under different anticoagulation schemes
        pre stroke [Non-vitamin K antagonists oral anticoagulants (NOAC, also referred to as novel
        or new oral anticoagulants), Vitamin K antagonists (VKA), and no oral anticoagulation.
        According to the type of stroke, patients will be enrolled in the ischemic or hemorrhagic
        stroke substudy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Ischemic stroke substudy:

        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  Informed consent

          -  Acute ischemic stroke with either symptoms lasting â‰¥ 24h or evidence of infarction in
             brain imaging

               -  Anticoagulation with NOAC

               -  Anticoagulation with VKA

               -  No anticoagulation

          -  Previous/present atrial fibrillation

        Exclusion Criteria:

          -  No informed consent

          -  Symptom-onset &gt; 24 h

        Hemorrhagic stroke substudy:

        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  Acute primary intracerebral hemorrhage

          -  - a) Anticoagulation with NOAC

          -  - b) Anticoagulation with VKA

          -  - c) No anticoagulation

          -  Previous/present atrial fibrillation

        Exclusion Criteria:

          -  No informed consent

          -  Symptom-onset &gt; 24 h
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Veltkamp, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University Hospital, Department of Neurology, Heidelberg, Germany; Department of Stroke Medicine, Imperial College London, London, United Kingdom.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roland Veltkamp, Prof. Dr. med.</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>38121</phone_ext>
    <email>r.veltkamp@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timolaos Rizos, MD</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>6999</phone_ext>
    <email>Timolaos.Rizos@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perdita Beck, SN</last_name>
      <phone>0049 6221 56</phone>
      <phone_ext>38121</phone_ext>
      <email>perdita.beck@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Prof. Roland Veltkamp</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Registry of Acute Stroke Under Novel Oral Anticoagulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

